Given that aberrant RET activity is an oncogenic driver in numerous cancers, RET is considered an optimal target for therapeutic intervention, first with multi-kinase inhibitors which were soon followed by the first generation of selective RET inhibitors. The gene discussed is RET; the disease is cancer.